Drugs group Shire Pharmaceuticals is trying to pacify investors angry over the shock departure of chief executive Rolf Stahel.
The company's American chairman Dr James Cavanaugh insisted Mr Stahel's decision to step down was not the result of a boardroom rift but succession planning.
He said the group would remain based in the UK as he tried to allay fears Shire was becoming too American.
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules hereComments are closed on this article